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Abstract
In line with the policy objectives of the United Nations Sustainable Development Goals, this commentary seeks to
examine the extent to which provisions of international health research guidance promote capacity building and
equitable partnerships in global health research. Our evaluation finds that governance of collaborative research
partnerships, and in particular capacity building, in resource-constrained settings is limited but has improved with
the implementation guidance of the International Ethical Guidelines for Health-related Research Involving Humans
by The Council for International Organizations of Medical Sciences (CIOMS) (2016). However, more clarity is needed
in national legislation, industry and ethics guidelines, and regulatory provisions to address the structural inequities
and power imbalances inherent in international health research partnerships. Most notably, ethical partnership
governance is not supported by the principal industry ethics guidelines – the International Conference on Harmonization
Technical Requirements for Registration of Pharmaceutical for Human Use (ICH) Good Clinical Practice (ICH-GCP). Given
the strategic value of ICH-GCP guidelines in defining the role and responsibility of global health research partners, we
conclude that such governance should stipulate the minimal requirements for creating an equitable environment of
inclusion, mutual learning, transparency and accountability. Procedurally, this can be supported by i) shared research
agenda setting with local leadership, ii) capacity assessments, and iii) construction of a memorandum of understanding
(MoU). Moreover, the requirement of capacity building needs to be coordinated amongst partners to support good
collaborative practice and deliver on the public health goals of the research enterprise; improving local conditions of
health and reducing global health inequality. In this respect, and in order to develop consistency between sources of
research governance, ICH-GCP should reference CIOMS ethical guidelines as the established standard for collaborative
partnership. Moreover, greater commitment and support should be given to co-ordinate, strengthen and enforce local
laws requiring equitable research partnerships and health system strengthening.
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Background
Health research is vital for better population health,
equity, and national development [1]. As stated in the
World Health Report 2013: ‘all nations should be
producers of research as well as consumers’ [2]. How-
ever, significant constraints on skills, expertise and
finance inhibit countries with limited resources from
carrying out such necessary research. In response, inter-
national collaborative research partnerships have formed
to bridge the health research gap in low- and middle-
income countries. This has resulted in the production of
new vital health data and scientific advancement, and
yet persisting capacity gaps and health capabilities con-
tinue to exist between countries. Although the reasons
for this reality are complex and multifaceted, one key as-
pect (the focus of this commentary) is achieving clarity
on the role and responsibility of international health re-
search partnerships in addressing matters of global
health. The stifled progress of global health research
activity is not so much a limitation in the science
(although this remains a factor in respect of some dis-
eases) but also an outcome of social and structural
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inequality [3]. This has affected global health priorities,
including which research agendas are funded, for which
target populations are health interventions designed, and
how the costs, risks and benefits of research are shared.
To date, partnership approaches have sustained old
ghosts: north-south dependency, distorted health
research priorities, weak and unprepared health care sys-
tems, underutilized local professionals and knowledge,
unfair distribution of risks and benefits and insufficient
access to life-saving interventions for populations most
in need [4, 5]. Such factors destabilize regional develop-
ment, health equity and the health of populations suffer-
ing from both endemic disease and poverty. Given this
question regarding the responsibilities of ethical partner-
ships, this commentary explores the extent to which
international health research guidelines and legislation -
a crucial source of governance - require equitable part-
nership structures, and in particular capacity building.
Fulfilling the obligation to engage in capacity building in
this context means the advancement of systems, expert-
ise and infrastructures of health research capabilities
through improvement to operational, institutional and
individual functions [6]. Capacity building is an ethical
obligation premised on the principles of social justice
and health equity; the principles respectively require the
equitable distribution of risks and benefits in health re-
search (social justice) and equal access to the resources
needed to improve and maintain positive health out-
comes (health equity) [7]. The objective of capacity
building is to “develop individuals, organizations and so-
cieties (individually and collectively) to perform func-
tions, effectively, efficiently and in a sustainable manner
to define objectives and priorities, build sustainable insti-
tutions and bring solutions to critical national problems”
[8]. As recognized by other authors, a strengthening
effect through partnership may also be possible in high-
income countries and across a broad variety of
collaborative arrangements [9].
Where governments are unable to sufficiently establish
the infrastructure, skills, and systems to conduct health
research, there is an ethical duty amongst the partners
of an international collaborative to build and support
capacity. This is crucial in respect of addressing public
health. For example, the process of building and
strengthening public health capacities (in part through
collaborative research) is necessary for the function and
effective implementation of the International Health
Regulations [10]; an international agreement of all WHO
member countries designed to strengthen health security
through sample collection and information sharing [11].
Failure to collaborate, or collaborate effectively, slows
national and global responses to disease threats and
places lives at risk, disproportionately affecting the most
vulnerable [12]. The need for capacity building to
establish equitable and sustainable collaborations is
strongly advocated by the UN Sustainable Development
Goals and the latest CIOMS ethical guidance update.
Practically, the commitment of partners to capacity
building is crucial for global health research to overcome
inherent power differentials within collaborative re-
search, to support local research-leadership and, to fully
engage and integrate research into local healthcare set-
tings. Fulfilling these capacity building objectives ensure
that health research is able to respond to local health
needs and can assure [13] the safety and health of local
and global populations [12].
Increasingly, international collaborative research is
being asked to consider the local interests of resource-
constrained partners and the responsibility of collabora-
tions to safeguard against the potential for structural
exploitation when operating in resource-constrained set-
tings [6, 14]. In some instances, research partnerships
have actively (and explicitly) incorporated capacity build-
ing objectives in conjunction with disease and interven-
tion research [4, 15–18]. This approach has not only
been regarded as ethical but also essential for respond-
ing to local health needs, through bolstering both the
health-related social structures, and addressing the
urgent health needs of the affected populations [6, 19].
Research collaborations are central to the exchange of
capacity. The professional and institutional links that
form within multinational networks create a
partnership-platform for expertise sharing, knowledge
transfer and system strengthening [12]. However, at-
tempts to establish effective capacity development ap-
proaches in global health research remain disjointed and
inconsistent [20].
The commentary in this instance reflects on collabora-
tive global health research partnerships operating in
resource-constrained settings. These settings are charac-
terised by poverty, weak healthcare systems, and high
burdens of diseases; conditions that disproportionately
affect disadvantaged populations and sustain vicious
cycles of impoverishment [21–23]. The major concern of
global health research is that despite increased invest-
ment in research programs with multiple international
partners, there has been much less advancement in low-
and middle-income countries accruing their own re-
search capacity and strengthened systems of health to
protect their populations [24]. This is ethically challen-
ging and compromises the overall goals of collaborative
research to improve public health and reduce global
health disparities [2, 4]. For global health research part-
nerships to successfully respond to the health needs of
vulnerable populations living in low-resource settings,
an international collaborative partnership must succeed
in addressing a range of complicated objectives: on the
one hand generating health data and generalizable
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knowledge (the scientific goals), whilst on the other
hand, attending to structural limitations of resources
and infrastructure (the capacity goals). This requires
navigating a diverse set of challenges including a range
of access barriers to effective interventions and under
developed health and research systems. Accounting for
these different goals is important to deliver on the over-
all public health objective of improving conditions of
health, both locally and globally.
The recognised need for global research capacity
worldwide represents a new shift in thinking, with the
objective being to provide all countries with health
capabilities to monitor, prioritize and maintain local con-
ditions of good health. This approach is founded on the
idea that there is no global health security, without glo-
bal health justice protecting health as a human right.
Meeting this commitment requires locally relevant,
system-integrated health research. The spread of the
Ebola and Zika viruses outbreaks are just two recent
cases that exemplify why local capacity is both urgent
and necessary to protect the health of populations both
within countries and worldwide [11, 25, 26].
A changing governance landscape
Over time, as global health research has advanced, legis-
lation and ethics guidelines have had to change, chal-
lenged with shifting paradigms: scientific advancement,
the recognition of human rights, societal development
and evolving international commitments. On the whole
however international health research governance and
guidance has been slow to, and inconsistent in, recogniz-
ing the principle of sustainable capacity building [27].
Endorsing the role of capacity building in partnerships
has been reinforced by the United Nations Sustainable
Development Goals (SDGs), 2015, (agreed upon by 193
countries) and the CIOMS guidelines (2016). These two re-
cently published guidance documents incorporate capacity
building into the standards they set, and this indicates com-
mitment to a change in approach, at least within policy. In
particular, Goal 17 of SDG states, “Enhance North-South,
South-South and triangular regional and international co-
operation on and access to science, technology, and
innovation and enhance knowledge sharing on mutually
agreed terms.” Additionally, Goal 17 also has a standalone
Capacity Building Task which states, “Enhance international
support for implementing effective and targeted capacity-
building in developing countries to support national plans
to implement all the sustainable development goals, includ-
ing through North-South, South-South, and triangular
cooperation.” These high-level international commitments
now need to be translated into practical activities on the
ground. The responsibility to do so rests with governments,
legislatures, industry, NGOs and civil society.
In line with this new agenda of capacity strengthening,
the latest version of the ethical research guidelines from
CIOMS (2016), provides structured guidance for fulfill-
ing capacity building objectives and equitable partner-
ship within programmes of collaborative research [28].
Focusing in on the structure and responsibilities of part-
nership recognizes all stakeholders as equal, shifting the
decision-making structure away from the donor-
recipient dynamic often present in north-south collabo-
rations. Addressing the ethics of the partnership in a
way that goes beyond traditional research ethics (sound
science, participant safety and autonomy), the CIOMS
guidelines identify a crucial point: the act of entering
into partnership has accompanying ethical responsibil-
ities. This marks the need for collaborative research
partnerships to contribute to sustainable capacity build-
ing activities that brings structured changes to local
skills, knowledge, and systems. This is important be-
cause aiming to combat one specific health disease
through collaborative research or even providing a one-
off research training amongst partners will not alone se-
cure conditions of good health for a population; co-ordi-
nated commitment towards institutional and national
capacity building is also required. Threats to health will
always evolve and emerge and therefore public health re-
quires the presence of functioning, and responsive,
health and research systems. As such, CIOMS guideline
states that research projects should have “local principal
investigators”. This requirement ensures community
consultation, context-relevant deliberative decision-
making and engagement with local partners and re-
search programs that integrate with local healthcare set-
tings. As stipulated by the updated Guideline 8,
“engaging with the community is necessary to deliver on
the social value of research and respect for individual
and community rights” [28]. To fulfil this objective, it is
important to have partnerships that are not led solely by
the funding partners, and this is achieved through eth-
ical partnership governance – good collaborative prac-
tice - that recognises the contribution (financial or
otherwise) or all partners [29, 30]. Structuring the part-
nership, decision-making and partner-roles through eth-
ical governance creates an equitable collaborative
environment of inclusion, transparency and accountabil-
ity [29]. Capacity strengthening objectives, are not
merely operational choices but ethical requirements to
achieve the necessary structural changes that establish
local leadership, mutual knowledge sharing, and a com-
mitment to regional health improvements [31].
Dominance of ICH - GCP
While the United Nations and CIOMS guidance adopts
a new and more promising approach, one significant
impediment acts as a barrier to translation of these
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essential principles into practice; the International Con-
ference on Harmonization Technical Requirements for
Registration of Pharmaceutical for Human Use (ICH)
Good Clinical Practice (ICH-GCP). ICH-GCP guide-
lines have come to define the obligations of the research
enterprise, and govern the role and responsibilities of
international health research programmes. However, the
adoption of ICH-GCP has been driven by the interests
of the pharmaceutical industry [32]. This has perpetu-
ated an overemphasis on clinical research guidelines
that is distinct from broader objectives of collaborative
research and, we argue, at odds with the objectives of
the UN Sustainable Development Goals. ICH-GCP sets
out to protect against human rights violations in health
research by referring to the Declaration of Helsinki
(DoH) and Nuremberg Code (and even in this respect
its success in achieving this aim has been questioned)
[33]. However, this narrow focus overlooks the partner-
ship issues of international collaborative health re-
search, with respect to ethical governance, social justice
and promoting equity, despite these being the practical
challenges of global health research today. As such, the
acquired superiority, and overwhelming reliance on
ICH-GCP as ethics guidance is problematic, and stands
at odds with the commitment of all sectors to imple-
ment strategies that fulfil the UN Sustainable Develop-
ment Goals. The aim of protecting participants from
harm has become too narrowly construed to the lim-
ited framework of the researcher-participant relation-
ship [5]. The harm or exploitation of a complex
multi-stakeholder collaborative partnership can be
much wider, and these concerns and risks need to be
addressed with the community and the healthcare
system where the research takes place [34]. At
present under ICH-GCP, poorly- resourced research
institutes are often instructed as service centers, ra-
ther than treated as equal collaborating partners. We
argue that greater consideration needs to be given to
Good Collaborative Practice, as well as Good Clinical
Practice. Inequitable partnerships pose a direct threat
to public health [30, 35]. Inherent injustice between
partners can lead to disruption in programmes of re-
search and public health [36, 37], compromise trust
in local and global systems and [11, 12]; may even
result in costly (time, money and reputation) legal
consequences [38]. It is most unfortunate that the
ICH did not take the opportunity of the revision of
GCP in 2016 to incorporate a statement on partner-
ship considerations and capacity building. During the
review process there were repeated calls for the guid-
ance to be updated with partnership governance and
greater consideration for the needs of resource-
constrained settings and yet, these safeguards have
not been incorporated into the new updates [39–41].
Recommendations: good collaborative practice
Moving forward, what changes are needed to incorpor-
ate sustainable capacity strengthening into collaborative
partnerships? One is to increase awareness amongst
global actors, funders, institutions, researchers and eth-
ical review boards. In particular, it should be noted that
the ICH-GCP requirements are ethically valid only to
the extent that proper procedure must be followed when
conducting health research; but this is only one criterion
for what makes health research ethically acceptable. The
ethical lens of good clinical practice needs to be widened
beyond the limited protection of the participant towards
a collectivist approach of good collaborative practice.
The interests of partners need not be the same, but
they should be reciprocal. Therefore we recommend the
process of creating a joint MoU to foster the spirit of
collaboration better. We further recommend that the
MoU could be a document with set criteria to direct
negotiations; for example, requiring details on the con-
stitution of the partnership and capacity strengthening
in relation to the individual, institutional and operational
obligations. The MOU process should be structured to
facilitate communication across partners of complex col-
laborative research. This approach is important for
defining the interests and needs of the various stake-
holders; the research priorities and; the joint capacity
agendas. Through co-operation partners can then form a
balanced operational relationship of understanding that
(fairly and transparently) allocates resources, responsibil-
ities and project ownership amongst all partners. The
partnership co-ordination set out in an MOU is crucial
for realising the shared responsibilities and rewards of
global health research. For example, establishing equit-
able partner inclusion on collaborative research protocol
design, project implementation, standards of care, data
handling, scientific analysis, authorship, intellectual
property rights and; access to novel health research and
innovation.
In the same way that an ethics committee examines an
informed consent form to ensure protection of individ-
ual participants, review of the memorandum of under-
standing would allow oversight of capacity strengthening
commitments, equitable resource allocation and evaluate
the social value of the study. Procedurally, the MoU
process could be stated in ICH-GCP and enforced
through national legislation in much the same way as is
seen with the participant informed consent process.
A second approach, beyond awareness and educa-
tion, would be to co-ordinate, strengthen and enforce
local laws requiring equitable research partnerships
and system strengthening. Clearer agreement within
guidance provisions in legislation would also have the
benefit of streamlining protocol reviews across differ-
ent ethical review boards and regulators, while also
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reducing procedural time delays, especially in multi-
center studies.
The third option would be to change the ICH-GCP
guidelines themselves to secure good collaborative prac-
tice through ethical partnership governance and capacity
strengthening requirements. This could have been done
in 2016, but the opportunity was missed. This approach
honours nation state sovereignty and promotes local
health research capabilities.
Conclusion
The long-term objective for the global health commu-
nity is to establish self-sufficient healthcare systems
worldwide that can undertake research and respond to
changing health environments. The need for autono-
mous and locally-led systems of health research has been
better recognized with international policy campaigns,
and in novel ethical research guidance. These sources
have adopted various conditions requiring that local cap-
acity building is supported in collaborative health
research. Arguably, no further progress in establishing
global health research systems will be achieved if the
limited scope of ICH-GCP continues to take priority, as
the only or overriding criteria of ethical health research.
At present, this international standard of health research
does not require capacity building, locally-led research
or even community engagement. We argue that this
needs to change. Ethical research requires that Good
Clinical Practice is complemented with Good Collabora-
tive Practice. Together, such guidance will govern
international health research partnerships that nuture
sustainable health research-, and health- systems in
accordance with their mission; to address global
health inequalities and improve local conditions of
health worldwide.
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